Entera Bio Ltd.

ENTX Healthcare Biotechnology

Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024.

Revenue
+200.0%
EPS
−133.3%
Free cash flow
−108.9%

Quarter to June 2026, against a year earlier

3.12 0.07 +2.30%
Market cap
$530.5M
P/E
0.0×
Fwd P/E
−8.0×
Dividend yield
—
F-score
n/a
Altman Z
6.22
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 5 6 4 — — —
P/E ratio
— — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
Altman Z-Score
— — (2.77) (3.47) (7.58) 7.95 (3.20) — 17.22 6.22
P/S ratio
— — 0.00 35.32 54.49 129.07 219.28 — 409.32 401.84
Altman Z″-Score (non-manufacturers)
— — (10.34) (9.93) (22.80) (0.98) (15.64) — (34.49) (20.27)
P/FCF ratio
— — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
Beneish M-Score
— — — 0.14 (2.67) (3.36) 0.28 — — —
P/Operating CF
— — (20.35) (8.11) (13.03) (29.34) (14.61) — (54.41) (48.89)
P/B ratio
— — 4.73 2.18 2.65 3.27 2.50 — 9.88 6.84
EV/Sales
— — 0.00 19.98 41.62 92.29 156.48 — 384.88 352.56
EV/EBITDA
— — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
EV/FCF
— — (4.08) (1.64) (1.43) (5.79) (1.67) — (10.99) (10.51)
Current Ratio
0.52 6.15 3.94 3.41 4.95 8.01 9.58 10.32 7.63 6.94
Net Debt/EBITDA
(3.85) 0.70 1.07 1.35 0.77 2.05 0.95 1.25 0.91 1.29
Debt/Equity
(1.02) (0.12) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
4.22% 39.42% 96.11% (97.98%) (115.46%) (81.04%) (76.17%) (80.30%) (103.34%) (108.01%)
ROA
(12.26%) (114.47%) (77.42%) (71.86%) (84.89%) (68.26%) (66.84%) (71.42%) (90.20%) (90.13%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
24.42% (105.59%) (108.12%) (95.99%) (150.35%) (54.59%) (112.23%) (86.59%) (121.49%) (86.47%)
Average Days of Receivables
— — 529.25 429.96 255.00 116.98 670.07 — 254.09 0.00
Earnings Yield
— — (39.26%) (41.59%) (55.91%) (16.54%) (44.12%) — (11.79%) (13.40%)
Free Cash Flow Yield
— — (20.61%) (34.47%) (53.34%) (12.35%) (42.70%) — (8.55%) (8.34%)
Free Cash Flow per Share
(0.27) (1.02) (1.24) (0.74) (0.58) (0.35) (0.44) (0.25) (0.18) (0.16)
Book value per Share
(2.17) (7.03) 1.27 0.98 0.41 0.86 0.41 0.36 0.21 0.28
Free Cash Flow
(3.14) (4.58) (9.86) (8.96) (10.61) (9.08) (12.55) (7.33) (6.82) (7.48)
EV/EBIT
— — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026